Author:
Ye Xiaolan,Ling Bai,Xu Hanrong,Li Gongqi,Zhao Xinguo,Xu Jiangyan,Liu Jun,Liu Liangeng
Funder
Youth Medical Talent of Jiangsu Province
Zhejiang Provincial Natural Science Foundation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference28 articles.
1. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial;Herbst;Lancet Oncol,2019
2. Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer;Cao;Toxicol Appl Pharmacol,2019
3. Inhibition of anaplerotic glutaminolysis underlies selenite toxicity in human lung cancer;Bruntz;Proteomics,2019
4. Opportunities and challenges of co-targeting epidermal growth factor receptor and autophagy signaling in non-small cell lung cancer;Wang;Oncol Lett,2019
5. A “triple whammy” in adenocarcinoma lung;Patro;Lung India,2019
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献